Genome-wide association studies (GWAS) have successfully identified approximately 36 psoriasis susceptibility loci. However, the causal variants at these loci remain largely unknown, and it is very likely that a large number of additional loci remain to be identified. In this proposal, we pursue a comprehensive strategy to identify both common and rare causal variants in psoriasis, and then perform targeted functional studies of these variants. In the first aim, we focus on the identification of common causal variants, the majority of which are expected to be regulatory. We improve statistical power by performing a meta-analysis of 5 European ancestry psoriasis GWAS totaling 4,832 cases and 10,103 controls, and further refine causal regions by comparison with 2 Asian ancestry psoriasis GWAS totaling 1,588 cases and 3,566 controls. From within causal regions, putative causal variants are identified using a novel bioinformatics approach that takes advantage of the recent release of a genome-wide map of human regulatory elements. Causal variants are further validated by follow-up genotyping in an independent sample of 11,141 cases and 11,020 controls. In the second aim, we focus on the identification of rare, coding variants. To increase our statistical power to detect rare variant associations, we perform exome sequencing of 500 severe-phenotype psoriasis cases and then impute the identified rare variants onto a GWAS cohort of 4,832 cases and 10,103 controls. Putative causal variants are again validated in independent cohorts. In the third aim, we create a psoriasis regulatory roadmap that defines how non-coding variants impact cell lineage specific gene expression, and further test coding variants for functional impact using cellular assays. Overall, the expected outcome of the proposed work will be first, a high quality list of putative causal SNPs at established psoriasis loci;second, the discovery of common and rare causal variants at novel loci;and third, the establishment of a roadmap by which we can understand the impact of these variants in specific cell types relevant to psoriasis. These advances will establish an important and necessary foundation that will guide future mechanistic studies of psoriasis and will identify new biological targets for therapy.

Public Health Relevance

Psoriasis is a debilitating, inflammatory skin disease that affects over 7 million Americans. Although genetic studies of psoriasis have thus far identified a number of gene variants linked to psoriasis, identifying the precise gene variants that cause psoriasis has remained elusive. In this proposal, we use large genetic datasets, novel bioinformatics methods, and the cutting-edge technologies to identify and characterize psoriasis causal variants, which may lead to new psoriasis therapies.

National Institute of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-GGG-C (50))
Program Officer
Cibotti, Ricardo
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
Schools of Medicine
San Francisco
United States
Zip Code
Abrouk, Michael; Nakamura, Mio; Zhu, Tian Hao et al. (2016) The Patient's Guide to Psoriasis Treatment. Part 3: Biologic Injectables. Dermatol Ther (Heidelb) 6:325-31
Farahnik, Benjamin; Nakamura, Mio; Singh, Rasnik K et al. (2016) The Patient's Guide to Psoriasis Treatment. Part 2: PUVA Phototherapy. Dermatol Ther (Heidelb) 6:315-24
Ahn, R S; Moslehi, H; Martin, M P et al. (2016) Inhibitory KIR3DL1 alleles are associated with psoriasis. Br J Dermatol 174:449-51
Gupta, Rashmi; Ahn, Richard; Lai, Kevin et al. (2016) Landscape of Long Noncoding RNAs in Psoriatic and Healthy Skin. J Invest Dermatol 136:603-9
Nititham, Joanne; Gupta, Rashmi; Zeng, Xue et al. (2016) Psoriasis risk SNPs and their association with HIV-1 control. Hum Immunol :
Singh, Rasnik K; Lee, Kristina M; Jose, Margareth V et al. (2016) The Patient's Guide to Psoriasis Treatment. Part 1: UVB Phototherapy. Dermatol Ther (Heidelb) 6:307-13
Tang, Ruqi; Wei, Yiran; Li, Zhiqiang et al. (2016) A Common Variant in CLDN14 is Associated with Primary Biliary Cirrhosis and Bone Mineral Density. Sci Rep 6:19877
Singh, Rasnik K; Lee, Kristina M; Vujkovic-Cvijin, Ivan et al. (2016) The role of IL-17 in vitiligo: A review. Autoimmun Rev 15:397-404
Ahn, Richard; Gupta, Rashmi; Lai, Kevin et al. (2016) Network analysis of psoriasis reveals biological pathways and roles for coding and long non-coding RNAs. BMC Genomics 17:841
Zhu, Tian Hao; Nakamura, Mio; Farahnik, Benjamin et al. (2016) The Patient's Guide to Psoriasis Treatment. Part 4: Goeckerman Therapy. Dermatol Ther (Heidelb) 6:333-9

Showing the most recent 10 out of 30 publications